Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of NS-035 in children with Fukuyama-type congenital muscular dystrophy
jRCT2031250858Phase 2Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Jun 2026
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NS-035 and Bronchitol in Fukuyama congenital muscular dystrophy (FCMD) (2 arms), sponsored by Nippon Shinyaku. Primary endpoint: Gross Motor Function Measure (GMFM-88) total score. Started Jun 2026; status: recruiting.
02
Drugs
NS-035Bronchitol
03
Conditions
Fukuyama congenital muscular dystrophy (FCMD)
Beyond the preview
Go deeper on jRCT2031250858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250858.